The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, United States
(PAI-1) Plasminogen Activator Inhibitor -1 Antigen
Time frame: Baseline (prior to surgery), On CPB for 30 minutes, At completion of CPB, and postoperative day 1 (at 8:00AM)postoperative day 1
t-PA (Tissue-type Plasminogen Activator) Antigen
Time frame: Baseline (prior to surgery) to postoperative day 1
IL-6 (Interleukin-6)
Time frame: Baseline (pre-surgery) to postoperative day 1
IL-8 (Interleukin-8)
Time frame: Baseline (pre-surgery) to postoperative day 1
(MAP) Mean Arterial Blood Pressure
Time frame: Baseline (prior to surgery) to postoperative day 1
Postoperative Bleeding
Chest tube output at 4 and 24 hours after completion of surgery
Time frame: 24 hours
Postoperative Renal Function
Acute kidney injury occurring
Time frame: Baseline (prior to surgery) to postoperative day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.